iRhythm Technologies Inc reports results for the quarter ended in January 1 - Earnings Summary

Reuters10-31

* iRhythm Technologies Inc reported a quarterly adjusted loss of $1.26​​ per share for the quarter ended January 1, lower than the same quarter last year, when the company reported EPS of -89 cents. The mean expectation of twelve analysts for the quarter was for a loss of 57 cents per share. Wall Street expected results to range from -67 cents to -46 cents per share.

* Revenue rose 18.4% to $147.54 million from a year ago; analysts expected $146.73 million.

* iRhythm Technologies Inc's reported EPS for the quarter was a loss of $1.48​.

* The company reported a quarterly loss of $46.18 million.

* iRhythm Technologies Inc shares had risen by 3.7% this quarter and lost 28.1% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had risen by about 3% in the last three months.​

* In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the advanced medical equipment & technology peer group is also "buy"

Wall Street's median 12-month price target for iRhythm Technologies Inc is $115.00 This summary was machine generated from LSEG data October 31 at 02:42 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 -0.57 -1.26 Missed

Jun. 30 2024 -0.89 -0.61 Beat

Mar. 31 2024 -0.96 -1.23 Missed

Dec. 31 2023 -0.59 -1.26 Missed

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment